Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a valuable class of drugs in the management of type 2 diabetes mellitus. These agents replicate the actions of naturally occurring GLP-1, enhancing insulin secretion and suppressing glucagon release. Recent studies have yielded a broad range of novel GLP-1 receptor agonists with impr

Breaking: Lilly Partners With US Firms to Make Mounjaro, Boost Supply Eli Lilly, now the world's most valuable healthcare company by market capitalization, has seen its shares soar 62.5% this year due to high demand for their diabetes drug Mounjaro. The company plans to invest $5.3 billion to expand production capacity for its widespread obesit